Unveiling the Power of VGL101: Vigil Neuroscience’s Groundbreaking Preclinical Findings for ALS and Alzheimer’s
Vigil Neuroscience Presents Preclinical Data on VGL101 for Adult-Onset Neurodegenerative Diseases CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) — Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today presented two posters at the Alzheimer’s Association International Conference (AAIC) in San Diego….